MedTrace Logo

Evaluation of a New Screening Method for Sarcopenia in Rheumatoid Arthritis

NCT04933097 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2024-05-17

No results posted yet for this study

Summary

Evaluation of a new screening method for sarcopenia in rheumatoid arthritis

Conditions

Interventions

DEVICE

Microfet2®

Conducting a day hospitalization including analyses: 1. Quantitative muscular analysis by measuring the DEXA of the whole body, the reference method for measuring body compartments and allowing the diagnosis of sarcopenia (IMMA\<7 in men and 5.5 in women) 2. Qualitative muscular analysis: * isokinetic measurement of muscular strength carried out on 3 muscle groups using a manual measurement sensor such as Microfet2 ® : quadriceps, triceps brachii, biceps * measurement of grip strength using Jamar® equipment validated as recommended by the EWGSOP * a walking test to assess the functional impact of sarcopenia and its severity

Sponsors & Collaborators

  • CHU de Reims

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-29
Primary Completion
2024-05-16
Completion
2024-05-16

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04933097 on ClinicalTrials.gov